Objective:

To discuss the prognostic value of MAdCAM-1 in metastatic renal cell carcinoma.

Approach:

Key Findings:

• Circulating MAdCAM-1 levels are prognostic of clinical outcomes in metastatic renal cell carcinoma.
• MAdCAM-1 serves as a dynamic biomarker for tracking gut dysbiosis-driven immune dysregulation.
• The MAdCAM-1 pathway could be a therapeutic target for microbiota-directed interventions.

Interpretation:

MAdCAM-1 levels can provide insights into patient prognosis and potential treatment strategies.

Limitations:

• Further research is needed to validate findings across diverse populations.
• The role of gut microbiota in immune regulation requires more exploration.

Conclusion:

MAdCAM-1 has potential as a biomarker and therapeutic target in treatment-resistant renal cell carcinoma.

Source

Based on findings from:

Marc Machaalani, MD on MAdCAM-1

Dana-Farber, 2025.

https://physicianresources.dana-farber.org/videos/marc-machaalani-md-on-madcam-1

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.